Clinical Trial Update: Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss [Phase 1, Phase 2]

View source ↗

Summary

Status update on a Phase 1/2 study of the selective PI3K-β inhibitor GSK2636771 in combination with pembrolizumab for metastatic melanoma with PTEN loss; the tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• GSK2636771
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING